Help appealing denials for this first oral on-demand treatment for HAE attacks.

Appeal Your Ekterly Denial

Get access to the first and only oral on-demand therapy for acute HAE attacks.

Start Your Appeal
Chat with AI Assistant

Understanding Your Ekterly (sebetralstat) Denial

Ekterly (sebetralstat) is the first and only oral on-demand treatment for acute hereditary angioedema (HAE) attacks in adults and adolescents 12 years and older. Unlike injectable treatments, you can take it as a pill when an attack starts. Insurance may prefer older injectable options, but oral therapy offers important convenience and faster treatment initiation.

Common Reasons for Denial

  • ! Prior authorization required
  • ! Must try injectable on-demand treatments first
  • ! HAE diagnosis not adequately documented
  • ! Attack frequency not documented
  • ! New drug with limited coverage policies
  • ! Orphan drug pricing concerns

How We Help

We help you document your HAE diagnosis, attack patterns, experience with injectable treatments, and why oral on-demand therapy is the appropriate choice for you.

Start your Ekterly appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Sebetralstat is an oral plasma kallikrein inhibitor that blocks the enzyme responsible for HAE attack symptoms.

✓ Clinical trials demonstrated significant reduction in attack severity and duration compared to placebo.

✓ Oral on-demand therapy eliminates barriers to treatment that exist with injectable options.

✓ Earlier treatment of HAE attacks leads to faster resolution and less severe symptoms.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

KalVista Cares (Ekterly) ↗

Eligible commercially insured patients may pay as little as $0 (up to $40,000 annual maximum). QuickStart program for coverage delays. Patient assistance available. Call 1-844-432-3322.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

US Hereditary Angioedema Association ↗

Nonprofit advocacy organization for people with HAE and their caregivers.

HAE International ↗

Global network of HAE organizations dedicated to improving lives of people with HAE.

Frequently Asked Questions

Oral therapy allows faster treatment initiation since you don't need to prepare an injection. It's also easier to carry and use in any setting, and some patients have needle phobia or difficulty with self-injection.

Document any issues with your current injectable, such as injection site reactions, difficulty self-injecting during attacks (shaking hands, swelling), needle phobia, or delays in treatment due to injection preparation.

Ekterly is designed for rapid absorption when taken orally at the start of an HAE attack. Clinical trials showed meaningful symptom relief within hours of dosing.

Ready to Fight Your Ekterly (sebetralstat) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including KalVista Pharmaceuticals. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.